Xi Qian

Kunming, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

Oxytocin suppresses endothelial-to-mesenchymal transition to mitigate cardiac fibrosis via the eNOS/cGMP/PKG pathway.

Oxytocin suppresses endothelial-to-mesenchymal transition to mitigate cardiac fibrosis via the eNOS/cGMP/PKG pathway.

Journal: Biochemical pharmacology
Published: June 10, 2026

Esketamine versus dexmedetomidine for oxygenation and postoperative quality of recovery in thoracoscopic surgery: a randomized, double-blind, non-inferiority controlled trial.

Esketamine versus dexmedetomidine for oxygenation and postoperative quality of recovery in thoracoscopic surgery: a randomized, double-blind, non-inferiority controlled trial.

Journal: Journal of anesthesia
Published: June 04, 2026

Oxytocin modulates glucose metabolism to protect against cardiac remodeling via the STAT3/eNOS Axis.

Oxytocin modulates glucose metabolism to protect against cardiac remodeling via the STAT3/eNOS Axis.

Journal: Cellular signalling
Published: May 14, 2026

Dexmedetomidine suppresses ferritinophagy-mediated ferroptosis in myocardial ischemia/reperfusion injury via the YAP1/NCOA4 pathway.

Dexmedetomidine suppresses ferritinophagy-mediated ferroptosis in myocardial ischemia/reperfusion injury via the YAP1/NCOA4 pathway.

Journal: Biochemical pharmacology
Published: November 21, 2025

Pathological mechanisms and clinical research progress of endothelial dysfunction.

Pathological mechanisms and clinical research progress of endothelial dysfunction.

Journal: Frontiers in cardiovascular medicine
Published: November 19, 2025

Oxytocin ameliorates cardiac hypertrophy by inhibiting mitochondrial dysfunction and pyroptosis via AMPK/PGC-1α /TFAM pathway.

Oxytocin ameliorates cardiac hypertrophy by inhibiting mitochondrial dysfunction and pyroptosis via AMPK/PGC-1α /TFAM pathway.

Journal: Life sciences
Published: November 13, 2025

Corrigendum to "Oxytocin attenuates cardiac hypertrophy by improving cardiac glucose metabolism and regulating OXTR/JAK2/STAT3 axis" [Peptides 182 (2024) 171323].

Corrigendum to "Oxytocin attenuates cardiac hypertrophy by improving cardiac glucose metabolism and regulating OXTR/JAK2/STAT3 axis" [Peptides 182 (2024) 171323].

Journal: Peptides
Published: January 10, 2025

Oxytocin attenuates cardiac hypertrophy by improving cardiac glucose metabolism and regulating OXTR/JAK2/STAT3 axis.

Oxytocin attenuates cardiac hypertrophy by improving cardiac glucose metabolism and regulating OXTR/JAK2/STAT3 axis.

Journal: Peptides
Published: October 04, 2024

Dexmedetomidine abates myocardial ischemia reperfusion injury through inhibition of pyroptosis via regulation of miR-665/MEF2D/Nrf2 axis.

Dexmedetomidine abates myocardial ischemia reperfusion injury through inhibition of pyroptosis via regulation of miR-665/MEF2D/Nrf2 axis.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: June 07, 2023

Dexmedetomidine attenuates myocardial ischemia/reperfusion-induced ferroptosis via AMPK/GSK-3β/Nrf2 axis.

Dexmedetomidine attenuates myocardial ischemia/reperfusion-induced ferroptosis via AMPK/GSK-3β/Nrf2 axis.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: July 20, 2022

Oxytocin ameliorates high glucose- and ischemia/reperfusion-induced myocardial injury by suppressing pyroptosis via AMPK signaling pathway.

Oxytocin ameliorates high glucose- and ischemia/reperfusion-induced myocardial injury by suppressing pyroptosis via AMPK signaling pathway.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: June 03, 2022

Effects of C-Reactive Protein on the Cardiac Differentiation of Mouse Embryonic Stem Cells.

Effects of C-Reactive Protein on the Cardiac Differentiation of Mouse Embryonic Stem Cells.

Journal: Biological & pharmaceutical bulletin
Published: September 03, 2015
Showing 1-12 of 12

Last Updated: 09/26/2026